Skip to main content
News Gregor Hagelüken 08.2022
PD Dr. Gregor Hagelueken (left) Dr. Martin Peter (right)
© Johann Saba / UKB

News categories: Publication

Structure of periplasmic TRAP transporter revealed

Elevator Tripartite ATP-independent periplasmic (TRAP) transporter shows a monomeric elevator architecture

Elevator Tripartite ATP-independent periplasmic (TRAP) transporters are found among various bacteria and archaea. They are situated in the periplasmic space and act as transport proteins for organic acids and related molecules. Though TRAP transporters are known to harbor two transmembrane domains and one soluble substrate-binding protein domain, until now the exact molecular structure remained elusive. Scientists of the excellence cluster ImmunoSensation2 at the University of Bonn in cooperation with colleagues of the University of York have now identified the structure of the TRAP transporter HiSiaQM. A functional analysis further revealed potential target areas for transporter inhibition. The study has now been published in the journal Nature Communications.

TRAP transporters help pathogens such as Haemophilus influenzae or Vibrio cholerae to evade the immune system. Sialic acid, which is ubiquitous in human tissue, is taken up by the pathogens via TRAP transporters. Subsequently, the organic acid is incorporated into the bacterial cell wall. "There, it serves as a kind of invisibility cloak for the bacteria to hide from our immune system," says Bonn scientist PD Dr Gregor Hagelueken. The pathogens mimic the surface of endogenous cells, where sialic acid frequently occurs in the form of cell surface glycoproteins.

The researchers from Hagelueken's group at the Institute of Structural Biology of the University Hospital Bonn (UKB) used cryo-electron microscopy (cryoEM) to decipher the structure of the transporter. "Our results represent a real breakthrough, since attempts to decipher the structure of a TRAP transporter had already been going on for about 20 years," says post-doctoral researcher Martin Peter from Bonn. He recalls the moment when it became clear that the monumental task had been accomplished: "At that moment, we were the first to ever see a TRAP transporter. It was then immediately clear to us how the protein works. It moves up and down like an elevator in the membrane.”

In collaboration with Prof. Dr. Ulrich Kubitscheck's group at the Clausius Institute for Physical and Theoretical Chemistry at the University of Bonn, the researchers were able to watch the transporter at work in real time. "The TRAP transporter is found in many disease-causing bacteria," says Hagelueken. "Maybe in the future our structure can help develop antibiotics to make sure the elevator gets stuck." The scientists were also able to generate several single variable domains on heavy chain (VHH) antibodies, binding to the periplasmic side of the TRAP transporter with high affinity. Application of the VHHs effectively inhibited the uptake of sialic acid. These insights into the functional mechanisms of TRAP transporter might help designing inhibitors for therapeutical use in the future.


Publication

Martin F. Peter, Jan A. Ruland, Peer Depping, Niels Schneberger, Emmanuele Severi, Jonas Moecking, Karl Gatterdam, Sarah Tindall, Alexandre Durand, Veronika Heinz, Jan Peter Siebrasse, Paul-Albert Koenig, Matthias Geyer, Christine Ziegler, Ulrich Kubitscheck, Gavin H. Thomas & Gregor Hagelueken: Structural and mechanistic analysis of a tripartite ATP-independent periplasmic TRAP transporter; Nature Communications; https://www.nature.com/articles/s41467-022-31907-y


Contact

PD Dr. Gregor Hagelueken

Institute for Structural Biology

University Hospital Bonn

Phone: +49 228 287-51200

Email: hagelueken(at)uni-bonn.de

Related news

Kathrin Leppek Publication PM

News categories: Publication

Starting points for the control of protein synthesis

Bonn researchers develop a versatile toolbox for the characterization of IRESes in cells.
View entry
Pandyra Publication Graphical Abstract

News categories: Publication

Genetic mutation affects survival after viral infection

Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

News categories: Publication

Potential target for MS therapy discovered

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry

Back to the news overview